Is BlackRock Virginia Municipal Bond Trust (BHV) a Buy, Sell, or Hold?
NYSE : BHV
BlackRock Virginia Municipal Bond Trust
$12.4 USD
$0 (0.0%)
- Volume
- 2.95K
- Average Volume
- 5.3K
- Market Capitalization
- $19.69M
- P/E Ratio
- -620.00
- Dividend Yield
- 4.60%
- Price Target
- Year High
- $13.30
- Year Low
- $10.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$36.38
- Current Ratio
- $77.63
Company Overview
NYSE
Charles Choon Sik Park
Asset Management - Bonds
Financial Services
BHV
N/A
US
USD
https://www.blackrock.com/investing/products/240231/blackrock-virginia-municipal-bond-trust-usd-fund
212 810 5300
092481100
0001169034
Liquidity Metrics
0.63
77.63
77.63
63.84
-36.38
Sales & Valuation
$1M
18.33
1.08
38.44
0.32
Profitability
-$0.94
-$1.49M
-2.49%
-2.49%
-0.15%
-0.09%
P/E Metrics
-620.00
0.55
0.55
Analyst Price Target & Rating
1/5
0 Analysts
%
Poll Results
About BlackRock Virginia Municipal Bond Trust (NYSE:BHV) Stock
The BlackRock Virginia Municipal Bond Trust (BHV) functions as a closed-end mutual fund, concentrating its investments within the fixed-income sector. Launched by BlackRock, Inc., the fund's investment management is handled by BlackRock Advisors, LLC. It primarily directs its capital towards the U.S. fixed income market, with a special focus on high-quality, investment-grade municipal bonds. These specific bonds offer the advantage of being exempt from both federal income taxes and personal income taxes in Virginia. This U.S.-domiciled trust began its operations on April 25, 2002. ...
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
2026-07-13 08:17:31
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform.
2026-06-29 07:30:00
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease. BHV-1300 targets the TSHR-IgG1 autoantibody that drives Graves' disease, not the thyroid gland itself.
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
2026-06-18 15:28:24
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors.
2026-06-01 07:30:00
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders First-in-human study initiated with dose escalation ongoing; preliminary data in healthy participants demonstrates favorable pharmacokinetics supporting convenient, once-daily dosing and well a tolerated profile at projected therapeutic exposures Penetrates blood-brain barrier and reverses metabolic dysfunction with 3-fold improvement in glucose utilization in human, whole brain model (Bexorg BrainEx platform, physiologically reactivated brains from human donors); preferential metabolic rescue in Alzheimer's disease donor brains vs controls Exhibits robust beneficial effects across a spectrum of preclinical models of Alzheimer's, and multiple sclerosis: restores metabolic deficits, reduces inflammation and neurodegeneration, and enhances remyelination PKM2 modulation offers a potential new paradigm for treating large, underserved, and high-value indications in neurology, ophthalmology, and immunology NEW HAVEN, Conn., June 1, 2026 /PRNewswire/ -- Biohaven Ltd.
2026-05-27 07:30:00
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TSHR-IgG1exceeding >80% over the 12-week study. Participants with Graves' overt hyperthyroidism, confirmed by elevated baseline thyroid tests despite being treated with anti-thyroid drug therapy (ATD), experienced normalization of thyroid hormones within weeks; T4 normalization occurring at a median of 3 weeks and T3 at a median of 5 weeks after the first administration of BHV-1300.
Frequently Asked Questions
-
What is the current BlackRock Virginia Municipal Bond Trust (BHV) stock price?
-
BlackRock Virginia Municipal Bond Trust(NYSE:BHV) stock price is $12.4 in the last trading session. During the trading session, BHV stock reached the peak price of $13.3 while $10.01 was the lowest point it dropped to. The percentage change in BHV stock occurred in the recent session was 0.0% while the dollar amount for the price change in BHV stock was $0.
-
BHV's industry and sector of operation?
-
The NYSE listed BHV is part of Asset Management - Bonds industry that operates in the broader Financial Services sector.
-
Who are the executives of BHV?
-
Walter C. O'Connor | Portfolio Manager
Charles Choon Sik Park | Chief Compliance Officer and Anti- Money Laundering Officer
Kevin Maloney | Portfolio Manager
Phillip Soccio | Portfolio Manager
| -
How many employees does BHV have?
-
Number of BHV employees currently stands at None. BHV operates from 55 East 52nd Street, New York City, NY 10055, US.
-
Link for BHV official website?
-
Official Website of BHV is: https://www.blackrock.com/investing/products/240231/blackrock-virginia-municipal-bond-trust-usd-fund
-
How do I contact BHV?
-
BHV could be contacted at phone #212 810 5300 and can also be accessed through its website. BHV operates from 55 East 52nd Street, New York City, NY 10055, US.
-
How many shares of BHV are traded daily?
-
The average number of BHV shares traded daily for last 3 months was 5.3K.
-
What is the market cap of BHV currently?
-
The market value of BHV currently stands at $19.69M with its latest stock price at $12.4